Amphastar Pharmaceuticals Income Statement (2013-2026) | AMPH

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	101.66M	112.20M	120.89M	120.37M	123.47M	120.13M	135.02M	140.02M	145.71M	180.56M	178.10M	171.84M	182.39M	191.21M	186.52M	170.53M	174.41M	191.84M	183.10M	171.17M
Cost of Revenue (Quarter)	54.29M	61.02M	64.65M	64.54M	60.11M	61.62M	63.85M	66.18M	72.97M	72.15M	81.97M	81.74M	87.23M	89.27M	99.88M	85.28M	87.92M	93.19M	97.44M	100.85M
Gross Profit (Quarter)	47.38M	51.18M	56.23M	55.83M	63.36M	58.51M	71.17M	73.84M	72.74M	108.40M	96.14M	90.10M	95.17M	101.94M	86.65M	85.25M	86.49M	98.65M	85.67M	70.32M
Operating items
Research & Development (Quarter)	4.13M	4.75M	47.52M	5.52M	5.76M	4.78M	17.24M	19.82M	16.84M	16.66M	8.62M	17.04M	9.01M	21.08M	10.42M	11.87M	20.08M	11.51M	10.28M	26.74M
Selling, General & Administrative (Quarter)	14.56M	10.91M	10.62M	12.47M	9.98M	11.98M	10.63M	13.48M	12.28M	12.65M	13.12M	15.68M	13.29M	14.82M	12.94M	16.00M	13.99M	39.47M	16.47M	18.03M
Other Operating Expenses (Quarter)	18.12M	10.76M	-26.16M	16.22M	22.80M	18.51M	5.47M	7.11M	6.72M	6.41M	20.42M	9.37M	18.82M	11.28M	26.75M	20.10M	10.23M	27.72M	32.04M	11.93M
Operating Expenses (Quarter)	36.82M	26.41M	31.98M	34.21M	38.53M	35.28M	33.34M	40.41M	35.84M	35.73M	42.16M	42.09M	41.12M	47.18M	50.11M	47.96M	44.31M	78.70M	58.79M	56.69M
Operating Income (Quarter)	10.56M	24.77M	24.25M	21.61M	24.82M	23.23M	37.83M	33.43M	36.90M	72.68M	53.98M	48.01M	55.22M	57.05M	45.14M	37.29M	42.18M	25.32M	35.61M	13.63M
EBIT (Quarter)	10.56M	24.77M	24.25M	21.61M	24.82M	23.23M	37.83M	33.43M	36.90M	72.68M	53.98M	48.01M	55.22M	57.05M	45.14M	37.29M	42.18M	25.32M	35.61M	13.63M
Non-operating items
Interest & Investment Income (Quarter)	0.14M	0.14M	0.16M	0.18M	0.23M	0.33M	0.58M	0.92M	1.03M	1.20M	2.30M	2.56M	3.34M	2.43M	2.29M	2.09M	1.92M	2.25M	2.42M	2.40M
Other Non Operating Income (Quarter)	3.60M	13.26M	2.92M	7.59M	-1.50M	-0.40M	3.38M	-0.39M	-1.52M	3.46M	-5.48M	5.92M	0.30M	-5.09M	2.95M	-2.23M	1.51M	0.23M	1.01M	0.57M
Non Operating Income (Quarter)	3.66M	12.88M	2.91M	7.42M	-1.67M	-0.63M	3.43M	0.14M	-4.09M	-9.04M	-12.63M	-0.13M	-4.97M	-9.37M	-1.18M	-6.43M	-2.85M	-3.81M	-3.69M	-3.58M
Net income details
EBT (Quarter)	14.22M	37.65M	27.16M	29.03M	23.15M	22.60M	41.26M	33.57M	32.81M	63.64M	-140.58M	47.88M	50.24M	47.68M	43.96M	30.86M	39.34M	21.51M	31.91M	10.05M
Tax Provisions (Quarter)	5.59M	6.69M	7.19M	4.08M	5.55M	6.56M	7.29M	6.75M	6.38M	14.03M	4.67M	4.13M	12.29M	7.25M	6.00M	5.58M	8.30M	4.16M	-15.67M	3.63M
Profit After Tax (Quarter)	7.77M	30.96M	19.76M	24.25M	17.35M	15.87M	35.09M	26.03M	26.12M	49.61M	38.15M	43.18M	37.95M	40.43M	37.39M	25.29M	31.03M	17.35M	24.43M	6.42M
Income from Non-Controlling Interests (Quarter)	-0.85M	1.41M
Income from Continuing Operations (Quarter)	8.62M	30.96M	19.97M	24.96M	17.60M	16.04M	33.97M	26.82M	26.43M	49.61M	-145.25M	43.75M	37.95M	40.43M	37.96M	25.29M	31.03M	17.35M	47.58M	6.42M
Consolidated Net Income (Quarter)	8.62M	30.96M	19.97M	24.96M	17.60M	16.04M	33.97M	26.82M	26.43M	49.61M	-145.25M	43.75M	37.95M	40.43M	37.96M	25.29M	31.03M	17.35M	47.58M	6.42M
Income towards Parent Company (Quarter)	8.62M	30.96M	19.97M	24.96M	17.60M	16.04M	33.97M	26.82M	26.43M	49.61M	-145.25M	43.75M	37.95M	40.43M	37.96M	25.29M	31.03M	17.35M	47.58M	6.42M
Net Income towards Common Stockholders (Quarter)	8.62M	30.96M	19.97M	24.96M	17.60M	16.04M	33.97M	26.82M	26.43M	49.61M	-145.25M	43.75M	37.95M	40.43M	37.96M	25.29M	31.03M	17.35M	47.58M	6.42M
Additional items
EPS (Basic) (Quarter)	0.18	0.64	0.42	0.52	0.36	0.33	0.70	0.56	0.55	1.02	-3.01	0.91	0.78	0.83	0.78	0.53	0.66	0.37	1.02	0.14
EPS (Diluted) (Quarter)	0.17	0.62	0.40	0.48	0.33	0.30	0.65	0.52	0.50	0.92	-2.74	0.83	0.73	0.78	0.73	0.51	0.64	0.36	0.99	0.14
Shares Outstanding (Quarter)	47.73M	48.02M	47.78M	48.14M	48.86M	48.90M	48.55M	48.00M	48.40M	48.70M	48.27M	48.21M	48.91M	48.62M	48.43M	47.64M	46.95M	46.47M	46.74M	45.32M
Shares Outstanding (Diluted) (Quarter)	49.55M	50.01M	49.78M	51.98M	53.23M	52.79M	52.43M	51.97M	53.10M	53.92M	53.00M	53.01M	52.05M	51.86M	52.06M	49.89M	48.13M	47.68M	48.22M	46.46M
EBITDA (Quarter)	10.56M	24.77M	24.25M	21.61M	24.82M	23.23M	37.83M	33.43M	36.90M	72.68M	53.98M	48.01M	55.22M	57.05M	45.14M	37.29M	42.18M	25.32M	35.61M	13.63M
Interest Expenses (Quarter)	43.99M	33.50M	0.17M	0.60M	138.66M	88.64M	1.75M	1.25M	481.98M	481.98M	-0.13M	8.63M	120.12M	168.76M	2.89M	7.58M	20.00M	33.33M	6.63M	7.29M
Tax Rate (Quarter)	39.35%	17.76%	26.49%	14.04%	23.98%	29.03%	17.67%	20.11%	19.46%	22.04%	-3.32%	8.62%	24.47%	15.21%	13.64%	18.07%	21.11%	19.35%	-49.10%	36.13%

Research Tools

Developers

Amphastar Pharmaceuticals Income Statement (2013-2026) | AMPH

Research Tools

Developers

Amphastar Pharmaceuticals Income Statement (2013-2026) | AMPH

Create an account

Sign In

Reset Password